{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:22:25Z","timestamp":1793658145945,"version":"4.5.1"},"reference-count":166,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jhep.2023.01.030","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T14:41:30Z","timestamp":1684334490000},"page":"1199-1215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-7980","authenticated-orcid":false,"given":"Aldo J.","family":"Montano-Loza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Rodr\u00edguez-Per\u00e1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George-Philippe","family":"Pageaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-3504","authenticated-orcid":false,"given":"Alberto","family":"Sanchez-Fueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-4350","authenticated-orcid":false,"given":"Sandy","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.01.030_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/lt.25411","article-title":"Not all cellular rejections are the same: differences in early and late hepatic allograft rejection","volume":"25","author":"Jadlowiec","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib3","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/ajt.13749","article-title":"Functional immune anatomy of the liver-as an allograft","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3748\/wjg.v25.i25.3123","article-title":"Revisiting the liver's role in transplant alloimmunity","volume":"25","author":"Abrol","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.030_bib5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2021.07.027","article-title":"Antibody-mediated rejection of the liver allograft: an update and a clinico-pathological perspective","volume":"75","author":"Lee","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib6","series-title":"Current status of ABO-incompatible liver transplantation","author":"Egawa","year":"2022"},{"key":"10.1016\/j.jhep.2023.01.030_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/00007890-200211150-00016","article-title":"Real-time monitoring of acute liver-allograft rejection using the Banff schema","volume":"74","author":"Demetris","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.510250328","article-title":"Banff schema for grading liver allograft rejection: an international consensus document","volume":"25","author":"Demetris","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.21280","article-title":"Liver biopsy interpretation for causes of late liver allograft dysfunction","volume":"44","author":"Banff Working","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cgh.2016.07.035","article-title":"Acute rejection increases risk of graft failure and death in recent liver transplant recipients","volume":"15","author":"Levitsky","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/lt.23788","article-title":"Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss","volume":"20","author":"O'Leary","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2022.06.015","article-title":"Acute Antibody-mediated rejection in liver transplantation: impact and applicability of the Banff working group on liver allograft pathology 2016 criteria","volume":"127","author":"Maurice","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2023.01.030_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/liv.15201","article-title":"Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients","volume":"42","author":"Meszaros","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib16","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.3748\/wjg.v27.i45.7771","article-title":"Chronic rejection after liver transplantation: opening the Pandora's box","volume":"27","author":"Angelico","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.030_bib17","first-page":"792","article-title":"Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection","volume":"31","author":"Demetris","year":"2000","journal-title":"Int Panel. Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/jlts.2002.36240","article-title":"The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic\u00a0liver transplantation: a systematic review","volume":"8","author":"Bartlett","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jhep.2021.08.007","article-title":"Non-invasive alloimmune risk stratification of long-term liver transplant recipients","volume":"75","author":"Vionnet","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/tri.12737","article-title":"Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal","volume":"29","author":"Rodriguez-Peralvarez","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13005","article-title":"An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation","volume":"31","author":"Rodriguez-Peralvarez","year":"2017","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/tri.12514","article-title":"Lack of agreement for defining \u2018clinical suspicion of rejection\u2019 in liver transplantation: a model to select candidates for liver biopsy","volume":"28","author":"Rodriguez-Peralvarez","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1432-2277.2012.01457.x","article-title":"Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count","volume":"25","author":"Rodriguez-Peralvarez","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib25","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/TP.0000000000004160","article-title":"New approaches to the diagnosis of rejection and prediction of tolerance in liver transplantation","volume":"106","author":"Taner","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOT.0000000000000959","article-title":"Biomarkers of rejection in liver transplantation","volume":"27","author":"Perottino","year":"2022","journal-title":"Curr Opin Organ Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib27","article-title":"Nucleic acid biomarkers to assess graft injury after liver transplantation","volume":"4","author":"Bardhi","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.01.030_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/lt.26272","article-title":"Monitoring of donor-derived cell-free DNA by short tandem repeats: concentration of total cell-free DNA and fragment size for acute rejection risk assessment in liver transplantation","volume":"28","author":"Fernandez-Galan","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/ajt.16835","article-title":"Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients","volume":"22","author":"Levitsky","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.647900","article-title":"Sensing acute cellular rejection in liver transplant patients using liver-derived extracellular particles: a prospective, observational study","volume":"12","author":"Kamali","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib31","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/ajt.15953","article-title":"Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation","volume":"20","author":"Levitsky","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.14348\/molcells.2016.0130","article-title":"Combined detection of serum IL-10, IL-17, and CXCL10 predicts acute rejection following adult liver transplantation","volume":"39","author":"Kim","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2023.01.030_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fimmu.2019.00873","article-title":"Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients","volume":"10","author":"Millan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib34","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/ajt.15828","article-title":"The molecular diagnosis of rejection in liver transplant biopsies: first results of the INTERLIVER study","volume":"20","author":"Madill-Thomsen","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib35","article-title":"Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis","volume":"3","author":"Rodriguez-Peralvarez","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2023.01.030_bib36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib37","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transpl Rev (Orlando)"},{"key":"10.1016\/j.jhep.2023.01.030_bib40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/cts.13276","article-title":"High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation","volume":"15","author":"Dopazo","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jhep.2023.01.030_bib41","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib42","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodriguez-Peralvarez","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2022.01.022","article-title":"Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation","volume":"77","author":"Montano-Loza","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/lt.25375","article-title":"Recurrent and de novo autoimmune hepatitis","volume":"25","author":"Stirnimann","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib45","first-page":"CD007606","article-title":"Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients","volume":"4","author":"Fairfield","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2023.01.030_bib46","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/SLA.0000000000000969","article-title":"Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study","volume":"260","author":"Lerut","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2023.01.030_bib47","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.030_bib48","article-title":"Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis","volume":"1","author":"Best","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2023.01.030_bib49","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.13182","article-title":"Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study","volume":"15","author":"TruneCka","year":"2015","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib50","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MOT.0000000000000069","article-title":"Liver transplantation: immunosuppression and oncology","volume":"19","author":"Rodriguez-Peralvarez","year":"2014","journal-title":"Curr Opin Organ Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546634.2019.1572864","article-title":"The association of mycophenolate mofetil and human herpes virus infection","volume":"31","author":"Yun","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jhep.2023.01.030_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2020.07.040","article-title":"Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients","volume":"74","author":"Colmenero","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib55","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/liv.15265","article-title":"Mycophenolate and SARS-CoV-2 vaccination: mixing oil and water","volume":"42","author":"Arenas-De Larriva","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib56","first-page":"21","article-title":"Activation of mTOR signaling pathway in hepatocellular carcinoma","author":"Ferrin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.01.030_bib57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ajt.12669","article-title":"Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus","volume":"14","author":"Jin","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib58","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial","volume":"17","author":"Saliba","year":"2017","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib59","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/TP.0000000000003394","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials","volume":"105","author":"Lee","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib60","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/lt.25400","article-title":"Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized trial","volume":"25","author":"Cillo","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib61","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/lt.26298","article-title":"Early everolimus-facilitated reduced tacrolimus in liver transplantation: results from the randomized HEPHAISTOS trial","volume":"28","author":"Nashan","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib63","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1097\/TP.0000000000002270","article-title":"Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation","volume":"102","author":"Rodriguez-Peralvarez","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib64","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.01.030_bib65","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2023.01.030_bib66","article-title":"CAQ corner: immune-mediated complications","author":"Thomson","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib67","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1007\/s10620-010-1149-x","article-title":"Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation","volume":"55","author":"Schmitt","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2023.01.030_bib68","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/0284186X.2021.1904520","article-title":"Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders","volume":"60","author":"Kinch","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jhep.2023.01.030_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000002650","article-title":"No gains in long-term survival after liver transplantation over the past three decades","volume":"269","author":"Rana","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2023.01.030_bib70","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.27538","article-title":"Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study","volume":"61","author":"Aberg","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib71","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodriguez-Peralvarez","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib72","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1097\/TP.0000000000002760","article-title":"Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation","volume":"103","author":"Rodriguez-Peralvarez","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib73","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib74","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.12118","article-title":"Long-term outcome of 'long-term liver transplant survivors","volume":"26","author":"Rubin","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib75","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.humimm.2017.10.007","article-title":"Tolerance in clinical liver transplantation","volume":"79","author":"Levitsky","year":"2018","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib76","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/lt.26219","article-title":"Metabolic complications in liver transplantation recipients: how we can optimize long-term survival","volume":"27","author":"Azhie","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib77","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.29578","article-title":"Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant","volume":"67","author":"Montano-Loza","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib78","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodriguez-Peralvarez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib79","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/lt.25963","article-title":"Improvements in disease-specific health-related quality of life of pediatric liver transplant recipients during immunosuppression withdrawal","volume":"27","author":"Mohammad","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trim.2008.08.007","article-title":"The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months","volume":"20","author":"Orlando","year":"2008","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1399-0012.2008.00944.x","article-title":"Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients","volume":"23","author":"Pons","year":"2009","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib82","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.26426","article-title":"Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients","volume":"58","author":"Benitez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib83","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/hep.31520","article-title":"Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving toward personalized management","volume":"73","author":"Feng","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib84","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hep.28681","article-title":"Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R","volume":"65","author":"Feng","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib85","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/ajt.13091","article-title":"Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation","volume":"15","author":"Scandling","year":"2015","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib86","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"Sanchez-Fueyo","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib87","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A\u00a0pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2022.08.035","article-title":"Low dose\u00a0interleukin-2 selectively expands circulating regulatory T cells but fails\u00a0to promote liver allograft tolerance in humans","volume":"78","author":"Lim","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib89","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/ajt.15205","article-title":"Outcomes of immunosuppression minimization and withdrawal early after liver transplantation","volume":"19","author":"Shaked","year":"2019","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib90","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2018.08.023","article-title":"Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants","volume":"155","author":"Feng","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.030_bib91","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.04.003","article-title":"Immunosuppression minimization vs. complete drug withdrawal in liver transplantation","volume":"59","author":"Londono","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib92","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.23481","article-title":"Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance","volume":"18","year":"2012","journal-title":"Liver Transpl"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2023.01.030_bib93","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 annual data report: liver","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib94","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.20213","article-title":"Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation","volume":"10","author":"McTaggart","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants","volume":"307","author":"Feng","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.01.030_bib96","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/TP.0b013e3182845f6c","article-title":"Late acute liver allograft rejection; a study of its natural history and graft survival in the current era","volume":"95","author":"Thurairajah","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib97","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/lt.23686","article-title":"Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance","volume":"19","author":"de la Garza","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib98","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.31036","article-title":"Immunosuppression withdrawal in liver transplant recipients on sirolimus","volume":"72","author":"Levitsky","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib99","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/lt.20155","article-title":"Older age and liver transplantation: a review","volume":"10","author":"Keswani","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib100","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.23534","article-title":"Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts","volume":"18","author":"Miyagawa-Hayashino","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib101","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.23854","article-title":"Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients","volume":"20","author":"O'Leary","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib102","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/TP.0000000000003034","article-title":"DSA are associated with more graft injury, more fibrosis, and upregulation of rejection-associated transcripts in subclinical rejection","volume":"104","author":"Hofer","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib103","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gastrohep.2019.09.010","article-title":"Donor-specific antibodies in liver transplantation","volume":"43","author":"Vionnet","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70938-7","article-title":"Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies","volume":"10","author":"Hofer","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.01.030_bib105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/petr.12116","article-title":"The use of transient elastography and non-invasive serum markers of fibrosis in pediatric liver transplant recipients","volume":"17","author":"Goldschmidt","year":"2013","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13125","article-title":"Transient elastography for non-invasive evaluation of post-transplant liver graft fibrosis in children","volume":"22","author":"Vinciguerra","year":"2018","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13541","article-title":"Late allograft fibrosis in pediatric liver transplant recipients: assessed by histology and transient elastography","volume":"23","author":"Chanpong","year":"2019","journal-title":"Pediatr Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib108","article-title":"Diagnostic performance of non-invasive tests for evaluation of hepatic graft fibrosis in pediatric liver transplantation: a scoping review","volume":"34","author":"Vo","year":"2020","journal-title":"Transpl Rev-Orlan"},{"key":"10.1016\/j.jhep.2023.01.030_bib109","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/lt.23391","article-title":"Transient elastography identifies liver recipients with nonviral graft disease after transplantation: a guide for liver biopsy","volume":"18","author":"Rigamonti","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/lt.24376","article-title":"Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation","volume":"22","author":"Crespo","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101606","article-title":"The use of transient elastography in identifying sub-clinical chronic ductopenic rejection in adult liver transplant recipients: a case series","volume":"73","author":"Lee","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib112","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/lt.26450","article-title":"Prediction of long-term morbidity and mortality after liver transplantation using two-dimensional shear wave elastography compared with liver biopsy","volume":"28","author":"Fallahzadeh","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib113","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/lt.26345","article-title":"A\u00a0diagnostic test meta-analysis evaluating imaging-based and blood biomarker-based assessment tools for fibrosis after liver transplantation","volume":"28","author":"Ng","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib114","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13700","article-title":"A\u00a0review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient","volume":"33","author":"Winters","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5604\/16652681.1198808","article-title":"Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: a pooled analysis","volume":"15","author":"Singh","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002286","article-title":"Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study","volume":"14","author":"Schutz","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib117","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/lt.26479","article-title":"Elevated fractional donor-derived cell-free DNA during subclinical graft injury after liver transplantation","volume":"28","author":"Baumann","year":"2022","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib118","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.21152","article-title":"Progressive histological damage in liver allografts following pediatric liver transplantation","volume":"43","author":"Evans","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib119","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/hep.22686","article-title":"Graft fibrosis after pediatric liver transplantation: ten years of follow-up","volume":"49","author":"Scheenstra","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib120","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/lt.21549","article-title":"Graft histology characteristics in long-term survivors of pediatric liver transplantation","volume":"14","author":"Ekong","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib121","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/lt.21781","article-title":"Late protocol liver biopsies in the liver allograft: a neglected investigation?","volume":"15","author":"Mells","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib122","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/jhep.2003.50231","article-title":"All liver recipients benefit from the protocol 10-year liver biopsies","volume":"37","author":"Sebagh","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib123","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/PAS.0b013e3181622490","article-title":"Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests","volume":"32","author":"Abraham","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2023.01.030_bib124","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/lt.24616","article-title":"Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments","volume":"22","author":"Kelly","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib125","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jhep.2018.04.012","article-title":"Molecular profiling of subclinical inflammatory lesions in long-term\u00a0surviving adult liver transplant recipients","volume":"69","author":"Londono","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/HMER.S278076","article-title":"The need for alternatives to liver biopsies: non-invasive analytics and diagnostics","volume":"13","author":"Neuberger","year":"2021","journal-title":"Hepat Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.32666","article-title":"Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts","volume":"77","author":"Wood-Trageser","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/TP.0b013e318195a7cb","article-title":"Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation","volume":"87","author":"Yoshitomi","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib129","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/TP.0b013e318176b1fd","article-title":"Protocol liver allograft biopsies","volume":"85","author":"Mells","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2023.01.030_bib130","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib131","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib132","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhep.2023.01.030_bib133","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib134","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2023.01.030_bib135","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study","volume":"69","author":"Parlati","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib136","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib137","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib138","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.2147\/OTT.S279858","article-title":"Adverse effects of immune-checkpoint inhibitors in hepatocellular carcinoma","volume":"13","author":"Cui","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jhep.2023.01.030_bib139","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 Comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib140","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a downstaging therapy for liver transplantation","volume":"72","author":"Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib141","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib142","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib144","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s12328-021-01521-4","article-title":"Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy","volume":"14","author":"Dehghan","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.030_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jhep.2023.01.030_bib146","doi-asserted-by":"crossref","first-page":"e1304","DOI":"10.1097\/TXD.0000000000001304","article-title":"Immune checkpoint inhibitor therapy before liver\u00a0transplantation-case and literature review","volume":"8","author":"Aby","year":"2022","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhep.2023.01.030_bib147","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A\u00a0pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2023.01.030_bib148","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jceh.2019.11.009","article-title":"Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab","volume":"10","author":"Amjad","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2023.01.030_bib149","article-title":"Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases","volume":"12","author":"Al Jarroudi","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jhep.2023.01.030_bib150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hbpd.2019.09.011","article-title":"Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation","volume":"19","author":"Zhuang","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhep.2023.01.030_bib151","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2174\/1568009620666200520084415","article-title":"Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: a case report and literature review","volume":"20","author":"Qiu","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jhep.2023.01.030_bib152","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/imt-2020-0014","article-title":"Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection","volume":"12","author":"Pandey","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jhep.2023.01.030_bib153","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/lt.25887","article-title":"Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors","volume":"27","author":"Shi","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib154","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/lt.25622","article-title":"Checkpoint inhibitor-induced rejection of a liver allograft: a combination of acute T cell-mediated and antibody-mediated rejection","volume":"25","author":"Lee","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2023.01.030_bib155","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdx548","article-title":"Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient","volume":"29","author":"Biondani","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2023.01.030_bib156","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2023.01.030_bib157","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.01.030_bib158","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver allograft failure after nivolumab treatment-A case report with systematic literature research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhep.2023.01.030_bib159","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review","volume":"28","author":"Kuo","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jhep.2023.01.030_bib160","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","author":"De Toni","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.01.030_bib161","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/L17-0187","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma","volume":"167","author":"Schvartsman","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2023.01.030_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jhep.2023.01.030_bib163","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.01.030_bib164","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mdx281","article-title":"Acute liver graft rejection after ipilimumab therapy","volume":"28","author":"Dueland","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2023.01.030_bib165","first-page":"211","article-title":"Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma","volume":"38","author":"Ranganath","year":"2015","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jhep.2023.01.030_bib166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:50:12Z","timestamp":1759175412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":166,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0168827823000892"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}